Ceruloplasmin and heart failure in the Atherosclerosis Risk in Communities study
Ceruloplasmin (Cp) decreases nitric oxide bioavailability in blood and has been associated with cardiovascular disease (CVD) in clinical studies. We assessed the associations between Cp and incident heart failure (HF), death, and CVD in the Atherosclerosis Risk in Communities (ARIC) study. Cp was me...
Gespeichert in:
| Veröffentlicht in: | Circulation. Heart failure 2013-09, Vol.6 (5), p.936-943 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 943 |
|---|---|
| container_issue | 5 |
| container_start_page | 936 |
| container_title | Circulation. Heart failure |
| container_volume | 6 |
| creator | Dadu, Razvan T Dodge, Rhiannon Nambi, Vijay Virani, Salim S Hoogeveen, Ron C Smith, Nicholas L Chen, Fengju Pankow, James S Guild, Cameron Tang, W H Wilson Boerwinkle, Eric Hazen, Stanley L Ballantyne, Christie M |
| description | Ceruloplasmin (Cp) decreases nitric oxide bioavailability in blood and has been associated with cardiovascular disease (CVD) in clinical studies. We assessed the associations between Cp and incident heart failure (HF), death, and CVD in the Atherosclerosis Risk in Communities (ARIC) study.
Cp was measured at ARIC visit 4 (1996-1998). We studied 9240 individuals without HF or CVD at ARIC visit 4 and followed them for a mean of 10.5 years. Genome-wide association study was performed to identify genetic determinants of Cp levels and evaluate their association with incident HF in ARIC participants. Cp levels (mean±SD) were higher in women versus men (335±79 versus 258±44 mg/L; P |
| doi_str_mv | 10.1161/circheartfailure.113.000270 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3908901</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1434022805</sourcerecordid><originalsourceid>FETCH-LOGICAL-c495t-8694ce6fd163e761e927de4458e6c3b19bcb09dabee3fa4b5e102e04950ce0a93</originalsourceid><addsrcrecordid>eNpVkV9LwzAUxYMoOqdfQQq--FK9adKuQRBGmToYKGN7Dml666L9M5NW2Lc3c3Poy004957fTTiEXFO4pTShd9pYvUJlu1KZqrfoVXYLANEIjsiACk5DFonR8eGeijNy7tw7QBLFsTglZxFLE8pTPiCvGdq-ateVcrVpAtUUwQ872MMDL3YrDMa-2NbpaluNC-bGfWx7WVvXfWM6gy5wXV9sLshJqSqHl_tzSJaPk0X2HM5enqbZeBZqLuIuTBPBNSZlQROGo4SiiEYFch6nmGiWU5HrHEShckRWKp7HSCFC8F7QCEqwIXnYcdd9XmOhsemsquTamlrZjWyVkf87jVnJt_ZLMgGpAOoBN3uAbT97dJ2sjdNYVarBtneScsYhilKI_ej9blT7zzuL5WENBbnNRGbTefY8Gc8Xj-PpbDmfeJXJXSbeffX3pQfvbwjsG74RjqM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1434022805</pqid></control><display><type>article</type><title>Ceruloplasmin and heart failure in the Atherosclerosis Risk in Communities study</title><source>MEDLINE</source><source>American Heart Association</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Dadu, Razvan T ; Dodge, Rhiannon ; Nambi, Vijay ; Virani, Salim S ; Hoogeveen, Ron C ; Smith, Nicholas L ; Chen, Fengju ; Pankow, James S ; Guild, Cameron ; Tang, W H Wilson ; Boerwinkle, Eric ; Hazen, Stanley L ; Ballantyne, Christie M</creator><creatorcontrib>Dadu, Razvan T ; Dodge, Rhiannon ; Nambi, Vijay ; Virani, Salim S ; Hoogeveen, Ron C ; Smith, Nicholas L ; Chen, Fengju ; Pankow, James S ; Guild, Cameron ; Tang, W H Wilson ; Boerwinkle, Eric ; Hazen, Stanley L ; Ballantyne, Christie M</creatorcontrib><description>Ceruloplasmin (Cp) decreases nitric oxide bioavailability in blood and has been associated with cardiovascular disease (CVD) in clinical studies. We assessed the associations between Cp and incident heart failure (HF), death, and CVD in the Atherosclerosis Risk in Communities (ARIC) study.
Cp was measured at ARIC visit 4 (1996-1998). We studied 9240 individuals without HF or CVD at ARIC visit 4 and followed them for a mean of 10.5 years. Genome-wide association study was performed to identify genetic determinants of Cp levels and evaluate their association with incident HF in ARIC participants. Cp levels (mean±SD) were higher in women versus men (335±79 versus 258±44 mg/L; P<0.0001), women on versus not on hormone-replacement therapy (398±89 versus 291±60 mg/L; P<0.0001), and African Americans versus whites (299±63 versus 293±74 mg/L; P=0.0005). After adjusting for traditional risk factors, high-sensitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide, and high-sensitivity cardiac troponin T, higher levels of Cp were associated with HF (hazard ratio, 1.44; 95% confidence interval, 1.13-1.83) and mortality (hazard ratio, 1.38; 95% confidence interval, 1.11-1.63). A locus on the ceruloplasmin gene on chromosome 3 was significantly associated with Cp levels (normal 295.56±77.60 mg/L; heterozygote 316.72±88.02 mg/L; homozygote 331.04±85.40 mg/L; P=8.3×10(-13)) but not with incident HF. After adjustment for traditional risk factors, Cp levels were also weekly associated with CVD.
Cp was associated with incident HF, mortality, and CVD in the ARIC population. A single locus on chromosome 3 was associated with Cp levels but not with HF.</description><identifier>ISSN: 1941-3289</identifier><identifier>EISSN: 1941-3297</identifier><identifier>DOI: 10.1161/circheartfailure.113.000270</identifier><identifier>PMID: 23861484</identifier><language>eng</language><publisher>United States</publisher><subject>African Americans - genetics ; Aged ; Atherosclerosis - blood ; Atherosclerosis - epidemiology ; Atherosclerosis - ethnology ; Atherosclerosis - genetics ; Atherosclerosis - mortality ; Biomarkers - blood ; Ceruloplasmin - analysis ; Ceruloplasmin - genetics ; Chromosomes, Human, Pair 3 ; Disease-Free Survival ; Estrogen Replacement Therapy ; European Continental Ancestry Group - genetics ; Female ; Genetic Predisposition to Disease ; Genome-Wide Association Study ; Heart Failure - blood ; Heart Failure - epidemiology ; Heart Failure - ethnology ; Heart Failure - genetics ; Heart Failure - mortality ; Humans ; Incidence ; Linear Models ; Male ; Middle Aged ; Polymorphism, Single Nucleotide ; Proportional Hazards Models ; Prospective Studies ; Risk Factors ; Time Factors ; United States - epidemiology</subject><ispartof>Circulation. Heart failure, 2013-09, Vol.6 (5), p.936-943</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c495t-8694ce6fd163e761e927de4458e6c3b19bcb09dabee3fa4b5e102e04950ce0a93</citedby><cites>FETCH-LOGICAL-c495t-8694ce6fd163e761e927de4458e6c3b19bcb09dabee3fa4b5e102e04950ce0a93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,3687,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23861484$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dadu, Razvan T</creatorcontrib><creatorcontrib>Dodge, Rhiannon</creatorcontrib><creatorcontrib>Nambi, Vijay</creatorcontrib><creatorcontrib>Virani, Salim S</creatorcontrib><creatorcontrib>Hoogeveen, Ron C</creatorcontrib><creatorcontrib>Smith, Nicholas L</creatorcontrib><creatorcontrib>Chen, Fengju</creatorcontrib><creatorcontrib>Pankow, James S</creatorcontrib><creatorcontrib>Guild, Cameron</creatorcontrib><creatorcontrib>Tang, W H Wilson</creatorcontrib><creatorcontrib>Boerwinkle, Eric</creatorcontrib><creatorcontrib>Hazen, Stanley L</creatorcontrib><creatorcontrib>Ballantyne, Christie M</creatorcontrib><title>Ceruloplasmin and heart failure in the Atherosclerosis Risk in Communities study</title><title>Circulation. Heart failure</title><addtitle>Circ Heart Fail</addtitle><description>Ceruloplasmin (Cp) decreases nitric oxide bioavailability in blood and has been associated with cardiovascular disease (CVD) in clinical studies. We assessed the associations between Cp and incident heart failure (HF), death, and CVD in the Atherosclerosis Risk in Communities (ARIC) study.
Cp was measured at ARIC visit 4 (1996-1998). We studied 9240 individuals without HF or CVD at ARIC visit 4 and followed them for a mean of 10.5 years. Genome-wide association study was performed to identify genetic determinants of Cp levels and evaluate their association with incident HF in ARIC participants. Cp levels (mean±SD) were higher in women versus men (335±79 versus 258±44 mg/L; P<0.0001), women on versus not on hormone-replacement therapy (398±89 versus 291±60 mg/L; P<0.0001), and African Americans versus whites (299±63 versus 293±74 mg/L; P=0.0005). After adjusting for traditional risk factors, high-sensitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide, and high-sensitivity cardiac troponin T, higher levels of Cp were associated with HF (hazard ratio, 1.44; 95% confidence interval, 1.13-1.83) and mortality (hazard ratio, 1.38; 95% confidence interval, 1.11-1.63). A locus on the ceruloplasmin gene on chromosome 3 was significantly associated with Cp levels (normal 295.56±77.60 mg/L; heterozygote 316.72±88.02 mg/L; homozygote 331.04±85.40 mg/L; P=8.3×10(-13)) but not with incident HF. After adjustment for traditional risk factors, Cp levels were also weekly associated with CVD.
Cp was associated with incident HF, mortality, and CVD in the ARIC population. A single locus on chromosome 3 was associated with Cp levels but not with HF.</description><subject>African Americans - genetics</subject><subject>Aged</subject><subject>Atherosclerosis - blood</subject><subject>Atherosclerosis - epidemiology</subject><subject>Atherosclerosis - ethnology</subject><subject>Atherosclerosis - genetics</subject><subject>Atherosclerosis - mortality</subject><subject>Biomarkers - blood</subject><subject>Ceruloplasmin - analysis</subject><subject>Ceruloplasmin - genetics</subject><subject>Chromosomes, Human, Pair 3</subject><subject>Disease-Free Survival</subject><subject>Estrogen Replacement Therapy</subject><subject>European Continental Ancestry Group - genetics</subject><subject>Female</subject><subject>Genetic Predisposition to Disease</subject><subject>Genome-Wide Association Study</subject><subject>Heart Failure - blood</subject><subject>Heart Failure - epidemiology</subject><subject>Heart Failure - ethnology</subject><subject>Heart Failure - genetics</subject><subject>Heart Failure - mortality</subject><subject>Humans</subject><subject>Incidence</subject><subject>Linear Models</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Proportional Hazards Models</subject><subject>Prospective Studies</subject><subject>Risk Factors</subject><subject>Time Factors</subject><subject>United States - epidemiology</subject><issn>1941-3289</issn><issn>1941-3297</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkV9LwzAUxYMoOqdfQQq--FK9adKuQRBGmToYKGN7Dml666L9M5NW2Lc3c3Poy004957fTTiEXFO4pTShd9pYvUJlu1KZqrfoVXYLANEIjsiACk5DFonR8eGeijNy7tw7QBLFsTglZxFLE8pTPiCvGdq-ateVcrVpAtUUwQ872MMDL3YrDMa-2NbpaluNC-bGfWx7WVvXfWM6gy5wXV9sLshJqSqHl_tzSJaPk0X2HM5enqbZeBZqLuIuTBPBNSZlQROGo4SiiEYFch6nmGiWU5HrHEShckRWKp7HSCFC8F7QCEqwIXnYcdd9XmOhsemsquTamlrZjWyVkf87jVnJt_ZLMgGpAOoBN3uAbT97dJ2sjdNYVarBtneScsYhilKI_ej9blT7zzuL5WENBbnNRGbTefY8Gc8Xj-PpbDmfeJXJXSbeffX3pQfvbwjsG74RjqM</recordid><startdate>20130901</startdate><enddate>20130901</enddate><creator>Dadu, Razvan T</creator><creator>Dodge, Rhiannon</creator><creator>Nambi, Vijay</creator><creator>Virani, Salim S</creator><creator>Hoogeveen, Ron C</creator><creator>Smith, Nicholas L</creator><creator>Chen, Fengju</creator><creator>Pankow, James S</creator><creator>Guild, Cameron</creator><creator>Tang, W H Wilson</creator><creator>Boerwinkle, Eric</creator><creator>Hazen, Stanley L</creator><creator>Ballantyne, Christie M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130901</creationdate><title>Ceruloplasmin and heart failure in the Atherosclerosis Risk in Communities study</title><author>Dadu, Razvan T ; Dodge, Rhiannon ; Nambi, Vijay ; Virani, Salim S ; Hoogeveen, Ron C ; Smith, Nicholas L ; Chen, Fengju ; Pankow, James S ; Guild, Cameron ; Tang, W H Wilson ; Boerwinkle, Eric ; Hazen, Stanley L ; Ballantyne, Christie M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c495t-8694ce6fd163e761e927de4458e6c3b19bcb09dabee3fa4b5e102e04950ce0a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>African Americans - genetics</topic><topic>Aged</topic><topic>Atherosclerosis - blood</topic><topic>Atherosclerosis - epidemiology</topic><topic>Atherosclerosis - ethnology</topic><topic>Atherosclerosis - genetics</topic><topic>Atherosclerosis - mortality</topic><topic>Biomarkers - blood</topic><topic>Ceruloplasmin - analysis</topic><topic>Ceruloplasmin - genetics</topic><topic>Chromosomes, Human, Pair 3</topic><topic>Disease-Free Survival</topic><topic>Estrogen Replacement Therapy</topic><topic>European Continental Ancestry Group - genetics</topic><topic>Female</topic><topic>Genetic Predisposition to Disease</topic><topic>Genome-Wide Association Study</topic><topic>Heart Failure - blood</topic><topic>Heart Failure - epidemiology</topic><topic>Heart Failure - ethnology</topic><topic>Heart Failure - genetics</topic><topic>Heart Failure - mortality</topic><topic>Humans</topic><topic>Incidence</topic><topic>Linear Models</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Proportional Hazards Models</topic><topic>Prospective Studies</topic><topic>Risk Factors</topic><topic>Time Factors</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dadu, Razvan T</creatorcontrib><creatorcontrib>Dodge, Rhiannon</creatorcontrib><creatorcontrib>Nambi, Vijay</creatorcontrib><creatorcontrib>Virani, Salim S</creatorcontrib><creatorcontrib>Hoogeveen, Ron C</creatorcontrib><creatorcontrib>Smith, Nicholas L</creatorcontrib><creatorcontrib>Chen, Fengju</creatorcontrib><creatorcontrib>Pankow, James S</creatorcontrib><creatorcontrib>Guild, Cameron</creatorcontrib><creatorcontrib>Tang, W H Wilson</creatorcontrib><creatorcontrib>Boerwinkle, Eric</creatorcontrib><creatorcontrib>Hazen, Stanley L</creatorcontrib><creatorcontrib>Ballantyne, Christie M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Circulation. Heart failure</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dadu, Razvan T</au><au>Dodge, Rhiannon</au><au>Nambi, Vijay</au><au>Virani, Salim S</au><au>Hoogeveen, Ron C</au><au>Smith, Nicholas L</au><au>Chen, Fengju</au><au>Pankow, James S</au><au>Guild, Cameron</au><au>Tang, W H Wilson</au><au>Boerwinkle, Eric</au><au>Hazen, Stanley L</au><au>Ballantyne, Christie M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ceruloplasmin and heart failure in the Atherosclerosis Risk in Communities study</atitle><jtitle>Circulation. Heart failure</jtitle><addtitle>Circ Heart Fail</addtitle><date>2013-09-01</date><risdate>2013</risdate><volume>6</volume><issue>5</issue><spage>936</spage><epage>943</epage><pages>936-943</pages><issn>1941-3289</issn><eissn>1941-3297</eissn><abstract>Ceruloplasmin (Cp) decreases nitric oxide bioavailability in blood and has been associated with cardiovascular disease (CVD) in clinical studies. We assessed the associations between Cp and incident heart failure (HF), death, and CVD in the Atherosclerosis Risk in Communities (ARIC) study.
Cp was measured at ARIC visit 4 (1996-1998). We studied 9240 individuals without HF or CVD at ARIC visit 4 and followed them for a mean of 10.5 years. Genome-wide association study was performed to identify genetic determinants of Cp levels and evaluate their association with incident HF in ARIC participants. Cp levels (mean±SD) were higher in women versus men (335±79 versus 258±44 mg/L; P<0.0001), women on versus not on hormone-replacement therapy (398±89 versus 291±60 mg/L; P<0.0001), and African Americans versus whites (299±63 versus 293±74 mg/L; P=0.0005). After adjusting for traditional risk factors, high-sensitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide, and high-sensitivity cardiac troponin T, higher levels of Cp were associated with HF (hazard ratio, 1.44; 95% confidence interval, 1.13-1.83) and mortality (hazard ratio, 1.38; 95% confidence interval, 1.11-1.63). A locus on the ceruloplasmin gene on chromosome 3 was significantly associated with Cp levels (normal 295.56±77.60 mg/L; heterozygote 316.72±88.02 mg/L; homozygote 331.04±85.40 mg/L; P=8.3×10(-13)) but not with incident HF. After adjustment for traditional risk factors, Cp levels were also weekly associated with CVD.
Cp was associated with incident HF, mortality, and CVD in the ARIC population. A single locus on chromosome 3 was associated with Cp levels but not with HF.</abstract><cop>United States</cop><pmid>23861484</pmid><doi>10.1161/circheartfailure.113.000270</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1941-3289 |
| ispartof | Circulation. Heart failure, 2013-09, Vol.6 (5), p.936-943 |
| issn | 1941-3289 1941-3297 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3908901 |
| source | MEDLINE; American Heart Association; EZB-FREE-00999 freely available EZB journals |
| subjects | African Americans - genetics Aged Atherosclerosis - blood Atherosclerosis - epidemiology Atherosclerosis - ethnology Atherosclerosis - genetics Atherosclerosis - mortality Biomarkers - blood Ceruloplasmin - analysis Ceruloplasmin - genetics Chromosomes, Human, Pair 3 Disease-Free Survival Estrogen Replacement Therapy European Continental Ancestry Group - genetics Female Genetic Predisposition to Disease Genome-Wide Association Study Heart Failure - blood Heart Failure - epidemiology Heart Failure - ethnology Heart Failure - genetics Heart Failure - mortality Humans Incidence Linear Models Male Middle Aged Polymorphism, Single Nucleotide Proportional Hazards Models Prospective Studies Risk Factors Time Factors United States - epidemiology |
| title | Ceruloplasmin and heart failure in the Atherosclerosis Risk in Communities study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T03%3A29%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ceruloplasmin%20and%20heart%20failure%20in%20the%20Atherosclerosis%20Risk%20in%20Communities%20study&rft.jtitle=Circulation.%20Heart%20failure&rft.au=Dadu,%20Razvan%20T&rft.date=2013-09-01&rft.volume=6&rft.issue=5&rft.spage=936&rft.epage=943&rft.pages=936-943&rft.issn=1941-3289&rft.eissn=1941-3297&rft_id=info:doi/10.1161/circheartfailure.113.000270&rft_dat=%3Cproquest_pubme%3E1434022805%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1434022805&rft_id=info:pmid/23861484&rfr_iscdi=true |